Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.19.3
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating expenses        
Research and development $ 5,250,327 $ 5,710,455 $ 14,161,543 $ 15,698,129
General and administrative 2,376,248 2,088,835 7,234,244 6,581,784
Total operating expenses 7,626,575 7,799,290 21,395,787 22,279,913
Loss from operations (7,626,575) (7,799,290) (21,395,787) (22,279,913)
Other income (expense):        
Interest income, net 80,747 174,778 334,307 490,170
Change in fair value of warrant liabilities 2,186,710 3,246,765 18,622,471 (21,830,377)
Total other income (expense) 2,267,457 3,421,543 18,956,778 (21,340,207)
Net loss $ (5,359,118) $ (4,377,747) $ (2,439,009) $ (43,620,120)
Basic and diluted net loss per share $ (0.07) $ (0.06) $ (0.03) $ (0.58)
Shares used in computing basic and diluted net loss per share 79,409,556 77,447,599 79,409,556 74,934,774